JPMorgan Chase & Co. Analysts Give MorphoSys (ETR:MOR) a €34.00 Price Target

JPMorgan Chase & Co. set a €34.00 ($35.79) price objective on MorphoSys (ETR:MORGet Rating) in a report issued on Wednesday, Borsen Zeitung reports.

A number of other equities research analysts also recently issued reports on MOR. Deutsche Bank Aktiengesellschaft set a €30.00 ($31.58) price target on MorphoSys in a research report on Tuesday, March 22nd. Berenberg Bank set a €65.00 ($68.42) price target on MorphoSys in a research report on Thursday, May 5th. Deutsche Bank Rese… set a €30.00 ($31.58) price objective on shares of MorphoSys in a research report on Wednesday, May 4th. Finally, Barclays set a €36.00 ($37.89) price objective on shares of MorphoSys in a research note on Thursday, March 17th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, MorphoSys has a consensus rating of Buy and a consensus target price of €51.25 ($53.95).

Shares of ETR:MOR opened at €18.46 ($19.43) on Wednesday. MorphoSys has a 12-month low of €18.84 ($19.83) and a 12-month high of €72.84 ($76.67). The company’s 50 day moving average price is €22.99 and its two-hundred day moving average price is €28.84. The firm has a market cap of $630.39 million and a PE ratio of -1.20. The company has a quick ratio of 3.79, a current ratio of 3.98 and a debt-to-equity ratio of 133.04.

MorphoSys Company Profile (Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

See Also

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.